Wednesday 17 July 2019 ,
Wednesday 17 July 2019 ,
Latest News
  • 73.93 pc pass HSC, equivalent examinations; 47,286 students secure GPA 5
  • Now food safety agency finds lead in milk of 11 brands
  • DU students demand ending affiliation with 7 colleges
  • Anti-mosquito drive from July 25: LGRD Minister
  • HSC results acceptable, good: PM
24 June, 2019 00:00 00 AM

FDA approves Zolgensma (onasemnogene abeparvovec-xioi) gene therapy to treat Spinal Muscular Atrophy

drugs.com
FDA approves Zolgensma (onasemnogene abeparvovec-xioi) gene therapy to treat Spinal Muscular Atrophy

The U.S. Food and Drug Administration recently approved Zolgensma (onasemnogene abeparvovec-xioi), the first gene therapy approved to treat children less than two years of age with spinal muscular atrophy (SMA), the most severe form of SMA and a leading genetic cause of infant mortality.

“The approval marks another milestone in the transformational power of gene and cell therapies to treat a wide range of diseases,” said Acting FDA Commissioner Ned Sharpless, M.D. “With each new approval, we see this exciting area of science continue to move beyond the concept phase into reality. The potential for gene therapy products to change the lives of those patients who may have faced a terminal condition, or worse, death, provides hope for the future. The FDA will continue to support the progress in this field by helping to expedite the development of products for unmet medical needs through the use of review pathways designed to advance innovative, safe and effective treatment options.”

SMA is a rare genetic disease caused by a mutation in the survival motor neuron 1 (SMN1) gene. The gene encodes the survival motor neuron (SMN) protein – a protein found throughout the body, which is critical for the maintenance and function of specialized nerve cells, called motor neurons. Motor neurons in the brain and spinal cord control muscle movement throughout the body. If there is not enough functional SMN protein, then the motor neurons die, leading to debilitating and often fatal muscle weakness.

SMA caused by mutations in the SMN1 gene is generally classified into several subtypes, based on the age of onset and severity; infantile-onset SMA is the most severe and most common subtype. Children with this condition have problems holding their head up, swallowing and breathing. These symptoms may be present at birth or may present by the age of 6 months.

“Children with SMA experience difficulty performing essential functions of life. Most children with this disease do not survive past early childhood due to respiratory failure” said Peter Marks, M.D., Ph.D., director of the FDA’s Center for Biologics Evaluation and Research. “Patients with SMA now have another treatment option to minimize the progression of SMA and improve survival. This approval demonstrates the continued momentum of this promising new area of medicine and the FDA’s commitment to supporting and helping expedite the development of these products.”

Zolgensma is indicated for the treatment of children less than two years of age with SMA. The product is an adeno-associated virus vector-based gene therapy that targets the cause of SMA. The vector delivers a fully functional copy of human SMN gene into the target motor neuron cells.

A one-time intravenous administration of Zolgensma results in expression of the SMN protein in a child’s motor neurons, which improves muscle movement and function, and survival of a child with SMA. Dosing is determined based on the weight of the patient.

The safety and effectiveness of Zolgensma is based on an ongoing clinical trial and a completed clinical trial involving a total of 36 pediatric patients with infantile-onset SMA between the ages of approximately 2 weeks and 8 months at study entry.

In this trial, there are 19 remaining patients, who range in age from 9.4 to 18.5 months; 13 of these 19 patients are at least 14 months of age. Compared to the natural history of patients with infantile-onset SMA, patients treated with Zolgensma also demonstrated significant improvement in their ability to reach developmental motor milestones (e.g., head control and the ability to sit without support).

The most common side effects of Zolgensma are elevated liver enzymes and vomiting. Zolgensma has a boxed warning that acute serious liver injury can occur. Patients with pre existing liver impairment may be at higher risk of experiencing serious liver injury.

Clinical examination and laboratory tests to assess liver function should be completed prior to treatment with Zolgensma, and patients’ liver function should be monitored for at least three months after Zolgensma administration.

Certain vaccines are contraindicated for patients on a substantially immunosuppressive steroid dose. Therefore, caregivers should consult with their healthcare professional to determine if adjustments to the patient’s vaccination schedule are necessary to accommodate concomitant corticosteroid administration.

Comments

Most Viewed
Digital Edition
More story
Editor Speaks

Editor Speaks

Reproductive life starts at puberty with onset of adult sexual life. Reproductive health is vital issue throughout the world as it concerned with population…
Sexual and reproductive health

Sexual and reproductive health

Good sexual and reproductive health is a state of complete physical, mental and social well-being in all matters relating to the reproductive system.…
Sexual health issues

Sexual health issues

Sexual health is a broad area that encompasses many inter-related challenges and problems. Key among the issues and concerns are human rights related…
Infertility & reproduction health

Infertility & reproduction health

Some fertility problems are more easily treated than others. In general, as a woman ages, especially after age 35, her chances of getting pregnant go…
Reproductive health and 
environmental exposure

Reproductive health and environmental exposure

The influence of the environment on human reproduction is a concern in all countries and anxiety has been increased following disasters such as those…

Understanding Premenstrual Syndrome

Premenstrual syndrome (PMS) is a condition that affects a woman’s emotions, physical health, and behavior during certain days of the menstrual cycle, generally just before her menses. PMS is a very common condition. Its symptoms affect more than 90 percent of menstruating women. It must impair…
The bamboo spine- Ankylosing spondylitis

The bamboo spine- Ankylosing spondylitis

Ankylosing Spondylitis means inflammation of the spine causing pain and stiffness of the back. When ankylosing spondylitis is not treated, it leads to…
Finger-prick blood test could help reduce antibiotic use for some patients

Finger-prick blood test could help reduce antibiotic use for some patients

A simple finger-prick blood test could help prevent unnecessary prescribing of antibiotics for people with the lung condition chronic obstructive pulmonary…
14 Natural remedies to beat insomnia

14 Natural remedies to beat insomnia

CATHY WONG Although it's common to have the occasional sleepless night, insomnia is the inability to sleep or excessive wakening in the night that…
Vaginal bacteria linked to ovarian cancer

Vaginal bacteria linked to ovarian cancer

Having too few "friendly" vaginal bacteria may increase a woman's chance of ovarian cancer, and swabs can be used to spot this, say researchers.…
For kids with rare condition, 'Restricted' diets can turn dangerous

For kids with rare condition, 'Restricted' diets can turn dangerous

Two young patients -- one 3 and the other 13 -- have a rare condition that calls for a highly restricted diet. Both have so much trouble eating that they…
Hospitalized pneumonia patients often get excess antibiotics

Hospitalized pneumonia patients often get excess antibiotics

Patients hospitalized with pneumonia often receive excess antibiotic therapy, according to a study published online July 9 in the Annals of Internal Medicine.…
Flu vaccine safe during pregnancy

Flu vaccine safe during pregnancy

Pregnant women can take comfort in new findings that suggest flu vaccines won't harm their fetuses. Canadian researchers examined data on more than…

Vyleesi bremelanotide for hypoactive sexual desire disorder

Vyleesi is a prescription medicine used to treat hypoactive (low) sexual desire disorder (HSDD) in women who have not gone through menopause, who have not had problems with low sexual desire in the past, and who have low sexual desire no matter the type of sexual activity, the situation, or the sexual…

Copyright © All right reserved.

Editor : M. Shamsur Rahman

Published by the Editor on behalf of Independent Publications Limited at Media Printers, 446/H, Tejgaon I/A, Dhaka-1215.
Editorial, News & Commercial Offices : Beximco Media Complex, 149-150 Tejgaon I/A, Dhaka-1208, Bangladesh. GPO Box No. 934, Dhaka-1000.

Editor : M. Shamsur Rahman
Published by the Editor on behalf of Independent Publications Limited at Media Printers, 446/H, Tejgaon I/A, Dhaka-1215.
Editorial, News & Commercial Offices : Beximco Media Complex, 149-150 Tejgaon I/A, Dhaka-1208, Bangladesh. GPO Box No. 934, Dhaka-1000.

Disclaimer & Privacy Policy
....................................................
About Us
....................................................
Contact Us
....................................................
Advertisement
....................................................
Subscription

Powered by : Frog Hosting